Silver Book Fact

Economic value from flu vaccine in elderly

As over 60% of the economic burden of influenza falls on those ages 65 and older, programs to reduce the impact of influenza on older Americans would have the greatest economic benefit.

Molinari, Noelle-Angelique M., Ismael R. Ortega-Sanchez, Mark L. Messonnier, William W. Thompson, Pascale M. Wortley, et al. The Annual Impact of Seasonal Influenza in the U.S.: Measuring disease burden and costs. Vaccine. 2007; 25: 5086-96. http://download.thelancet.com/flatcontentassets/H1N1-flu/epidemiology/epidemiology-14.pdf

Reference

Title
The Annual Impact of Seasonal Influenza in the U.S.: Measuring disease burden and costs
Publication
Vaccine
Publication Date
2007
Authors
Molinari, Noelle-Angelique M., Ismael R. Ortega-Sanchez, Mark L. Messonnier, William W. Thompson, Pascale M. Wortley, et al.
Pages
5086-96
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • ~One-third of shingles death preventable with vaccine
    Approximately one-third of shingles deaths may be preventable through vaccination.  
  • Life years saved from infectious disease eradication
    Infectious disease eradication in the U.S. led to the following annual life years saved (LYS): 5,811,852 for measles 42,702 for tetanus 212,690 for polio 1,685,740 for smallpox  
  • Pertussis vaccination reduced global cases
    Vaccination helped reduce global pertussis (whooping cough) cases from 3 million per year to less 250,000.  
  • Drastic reduction of morbidity from vaccine-preventable disease in 20th century
    In the 20th century, vaccines have reduced the morbidity from vaccine-preventable diseases by as much as 89–100%.  
  • Use of shingles vaccines significantly reduced disease burden
    Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the burden of illness from shingles by 61.1% and the incidence of postherpetic neuralgia (PHN) by 66.5%.